Company

Management Team

Brian O'Callaghan
President and Chief Executive Officer

David Renas, JD
Chief Financial Officer and General Counsel

Don Brown
Chief Operating Officer

Frank V. McL. Booth, MA MSc BM BCh FACS
Chief Medical Officer

Kenneth E. Burhop, PhD
Chief Scientific Officer

Clive Bertram
Chief Commercial Officer

Kristine Figueroa
Vice President of Human Resources

Mary Rose Keller
Vice President of Clinical Operations

Carmen Betancourt-Riche, MBA
Vice President of Regulatory Affairs and Quality Assurance

Brian O'Callaghan

President and Chief Executive Officer

Mr. O'Callaghan joined Sangart as President and Chief Executive Officer in June 2008. Mr. O'Callaghan brings a breadth of experience to Sangart, having held senior positions with a number of pharmaceutical and biotechnology companies in both Europe and the US. These include senior positions with Pfizer in the UK and Merck Serono in Germany, before becoming President and CEO of BioPartners, a Swiss based biotechnology company. Since relocating to the US, Mr. O'Callaghan has held senior management positions at Novartis, where he served as General Manager of their Transplantation, Immunology and Infectious Disease businesses, as well as at Covance, a clinical research firm, where he served as General Manager of their Cardiac safety and IVRS businesses. Mr. O'Callaghan joins Sangart from NPS Pharmaceuticals, where he served as Chief Commercial Officer. Mr. O'Callaghan brings his extensive general management background in the pharmaceutical, biotechnology and clinical research sectors, as well as his significant international experience, to lead Sangart through regulatory submission and commercial launch of MP4.

David Renas, JD

Chief Financial Officer and General Counsel

Mr. Renas has more than 25 years of experience in financial and legal matters, including service as Sangart's Chief Financial Officer and General Counsel since January 2002. Prior to joining Sangart, Mr. Renas was engaged as an attorney in private practice with Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner and as a Certified Public Accountant with Deloitte Haskins & Sells (now Deloitte & Touche). He also served as an accounting instructor at San Diego State University and has authored several law articles. Mr. Renas holds a Bachelor of Arts degree in Economics from Stanford University and a Juris Doctorate from the University of California at Davis.

Don Brown

Chief Operating Officer

Mr. Brown joined Sangart in April, 2009 as Chief Operating Officer. Prior to Sangart, he served as President & COO of Zosano Pharma in Fremont, CA. While with Zosano he oversaw the highly successful conclusion of a Phase 2 clinical trial, raised an additional $30 million Series C financing round from existing venture capital investors, and led the business development activities to a successful partnering conclusion prior to leaving. Prior to Zosano, Mr. Brown served as Senior Executive Vice President at Aventis with global responsibility for manufacturing, engineering, quality assurance, supply chain, and purchasing operations. Mr. Brown was also a co-founder of Calvert Laboratories in 1998. Calvert is a Pharmacology/Toxicology firm providing preclinical and environmental services to a vast number of companies in North America. A chemist by education, Mr. Brown has enjoyed a career of continued growth in the pharmaceutical industry, and has spent much of his career in the international arena negotiating with foreign governments and building manufacturing plants in six (6) countries.

Frank V. McL. Booth, MA MSc BM BCh FACS

Chief Medical Officer

Frank Booth is a native of the United Kingdom. He received his undergraduate, postgraduate and medical training at Oxford University. In addition he studied engineering as applied to Medicine at Imperial College in London. He trained in trauma at the Maryland Institute for Emergency medicine (MIEMS) unit in Baltimore and has held faculty appointments at Johns Hopkins and at the State University of New York at Buffalo where he led the division of Surgical Critical Care. He brings over 20 years of experience as a trauma and critical care surgeon and as a clinical investigator to Sangart. Prior to joining Sangart he worked in clinical development roles at Novo Nordisk and at Eli Lilly & Company.

Kenneth E. Burhop, PhD

Chief Scientific Officer

Dr. Burhop joined Sangart in January 2011 as Chief Scientific Officer. Prior to joining Sangart, he was the Global Scientific Lead/CSO for Baxter Healthcare Corporation's Medication Delivery Division and Vice President of R&D for Baxter's Biopharmaceutical Technologies business. Previously at Baxter, he assumed positions of increasing responsibility in Baxter's Hemoglobin Therapeutics Program, ultimately being named project leader and vice president of R&D for the Second Generation Recombinant Hemoglobin Program. Dr. Burhop's primary research expertise is in the area of cardiopulmonary pathophysiology, especially as it relates to inflammation, shock, material/drug biocompatibility assessment, and the roles of various inflammatory mediators and autacoids in causing acute lung injury. His focus for the past 20+ years has been on the safety and efficacy assessment of hemoglobin therapeutic products, including, most recently, recombinant-based hemoglobin products. His research has involved collaborations with more than 50 leading academic institutions and thought leaders from around the world. He has authored over 40 publications, more than 70 abstracts, several book chapters, has been invited to speak at numerous international meetings and symposia, and has either authored or co-authored numerous preclinical reports and regulatory filings in Europe and in the U.S., and has a number of issued patents. Dr. Burhop is a recognized international expert in the field of hemoglobin therapeutics. Dr. Burhop received his Bachelor's degree in zoology from the University of Wisconsin-Milwaukee, a Master of Science degree in veterinary science/physiology from the University of Wisconsin-Madison and a PhD in veterinary science/physiology, also from the University of Wisconsin-Madison. He completed an NIH Pulmonary Research Postdoctoral Fellowship in the Department of Physiology (also a Co-investigator on Lung Program Project) at the Albany Medical College, Albany, New York.

Clive Bertram

Chief Commercial Officer

Mr. Bertram joined Sangart in December 2008. He brings over 15 years of strategic marketing and sales experience in both international and local markets. Prior to Sangart he has held senior strategic marketing positions in a number of pharmaceutical and biopharmaceutical companies. These include Senior Director of International Marketing at Pharmion, European Marketing Director at Chiron Biopharmaceuticals, Global Commercial Development at Celltech, as well as several Sales & Marketing positions at Eli Lilly and Company. He is an experienced leader across many functions and countries with a specific focus on development and implementation of strategic and operational plans from early disease strategy through development and launch to established brands.

Kristine Figueroa

Vice President of Human Resources

Ms. Figueroa joined Sangart in November, 2008. Ms. Figueroa brings more than 13 years of experience in human resources. Prior to joining Sangart, Ms. Figueroa held senior management positions at SGX Pharmaceuticals and Kintera overseeing the Human Resources function. Ms. Figueroa also held management positions as a HR business partner and compensation professional with Elan Pharmaceuticals. Ms. Figueroa holds a B.S. in Business Administration and a M.S. in Human Resources Management from Troy State University. Ms. Figueroa holds certifications as a Certified Compensation Professional (CCP) and Global Remuneration Professional (GRP) through World at Work.

Mary Rose Keller

Vice President of Clinical Operations

Ms Keller joined Sangart as Vice President of Clinical Operations in December 2011. Ms Keller has more than 25 years of experience in clinical research and clinical trial execution. She began her career as a Research Associate at the Cancer Research Institute at University of California, Davis and San Francisco campuses with responsibility to oversee key programs including collaboration with the NCI for the early Interleukin-2 LAK cell programs. Subsequently Ms Keller moved into industry positions of increasing responsibility including oversight of numerous successful regulatory submissions, initially working with a contract research organization, and then with Agouron, Pfizer, and Shire Pharmaceuticals. She has also worked with companies involved in molecular diagnostics and personalized medicine. She has an undergraduate degree from the University of California, Davis and Executive Management and Leadership Training from Wharton. Ms Keller is a long term member of the Advisory Board for IIR Partnerships with Clinical Trials, and is Chairman of the External Advisory Board, SoCal HBA 2011-12.

Carmen Betancourt-Riche, MBA

Vice President of Regulatory Affairs and Quality Assurance

Ms. Betancourt-Riche joined Sangart as Vice President of Regulatory Affairs and Quality Assurance in January 2012. She has over 34 years of drug development experience in the pharmaceutical industry and has held senior management positions in Regulatory Affairs as well as Quality and Project Management. These include positions with Cerexa, KaloBios Pharmaceuticals, VaxGen, Coulter Pharmaceuticals, and Genentech. Ms. Betancourt-Riche joins Sangart from BioMarin Pharmaceutical where she served as Senior Advisor in Regulatory Research. Ms. Betancourt-Riche received her Bachelor’s Degree in Biological Sciences from the University of California at Davis and a M.B.A in International Corporate Management from Golden Gate University in San Francisco.